Headache Disorders, Primary: Clinical Trials

3 trials for Headache Disorders, Primary, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 enrolling by invitation. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Enrolling by invitation 3
Phase 21Enrolling by invitation 1

Follow Headache Disorders, Primary: new trials by email Literature Review of Headache Disorders, Primary trials Research Report on Headache Disorders, Primary

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
Eptinezumab, Standard of Care - Migraine, Chronic Migraine
Phase 3Enrolling by invitationDr George Medvedev1022025-05-052026-09-30
The Effectiveness of CBD and CBN in the Treatment of Facial Pain and Headache of Muscular Origin
An aqueous solution containing CBD and CBN, The aqueous solution of placebo - Myalgia, Muscle Pain
Phase 2 / Phase 3Enrolling by invitationWroclaw Medical University422025-04-012026-03-06
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
Ubrogepant - Migraine
Phase 3Enrolling by invitationAbbVie12002022-01-142025-07-20

Narrower conditions

Migraine Disorders (2)  ·  Emergencies (1)  ·  Facial Pain (1)  ·  Headache (1)  ·  Myalgia (1)  ·  Tension-Type Headache (1)

Broader conditions

Brain Diseases (3)  ·  Central Nervous System Diseases (3)  ·  Headache Disorders (3)  ·  Nervous System Diseases (3)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Disease Attributes (1)  ·  Muscular Diseases (1)  ·  Musculoskeletal Diseases (1)  ·  Musculoskeletal Pain (1)  ·  Neurologic Manifestations (1)  ·  Neuromuscular Diseases (1)  ·  Pain (1)  ·  Pathologic Processes (1)  ·  Signs and Symptoms (1)

Interventions

Cannabinol (1)  ·  Standard of Care (1)  ·  eptinezumab (1)  ·  ubrogepant (1)

Sponsors

AbbVie (1)  ·  Dr George Medvedev (1)  ·  Wroclaw Medical University (1)

Countries

Canada (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  United States (1)